Omeros Corporation (OMER) saw its stock increase following the announcement of the initial commercial shipments of Yartemlea. This therapy, approved by the FDA in December, targets thrombotic microangiopathy associated with hematopoietic stem cell transplants. The condition, with a severe case mortality rate exceeding 90%, now has a treatment option for patients aged two and above. Omeros has started fulfilling orders from multiple transplant centers, offering hope to both adults and children, including those unresponsive to previous treatments.
https://www.gurufocus.com/news/8556116/omeros-omer-rises-on-first-shipments-of-yartemlea
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.